Ethnicity and Pain Reviewed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ALBUQUERQUE-"Ethnicity is a relatively understudied concept in pain medicine," David B. Morris, PhD, writes in his review of ethnicity and pain (Pain Clinical Updates vol. IX, no. 4, November 2001). Existing research, he said, has provided "few firm generalizations" about the relationship between ethnicity and pain. This is due, in part, to the fact that both pain and ethnicity are "multidimensional, malleable, and shaped by culture."

ALBUQUERQUE—"Ethnicity is a relatively understudied concept in pain medicine," David B. Morris, PhD, writes in his review of ethnicity and pain (Pain Clinical Updates vol. IX, no. 4, November 2001). Existing research, he said, has provided "few firm generalizations" about the relationship between ethnicity and pain. This is due, in part, to the fact that both pain and ethnicity are "multidimensional, malleable, and shaped by culture."

Some studies suggest that minorities are less likely to receive adequate treatment for pain. Dr. Morris pointed to a US study that found no differences in the amount of opioid self-administered for acute pain among different ethnic groups, but significant differences in the amount of opioid prescribed.

Even when the prescription is adequate, he noted, "ethnic groups face inequalities that translate into poorly controlled pain." For example, pharmacies in poor, nonwhite neighborhoods may not stock adequate supplies of opioids.

Finally, Dr. Morris emphasized that although there may be measurable differences in how different ethnic groups experience pain, there are also "deep similarities." Studies of specific conditions, from cancer to childbirth, have found "major similarities among various ethnocultural groups in pain perception and response," he said.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content